ClinicalTrials.gg
CompletedNCT02489903Updated Mar 17, 2025Results posted

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

A Phase 2 interventional study of RRx-001 and Cisplatin in Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung and Neuroendocrine Tumors, sponsored by EpicentRx, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by EpicentRx, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Carcinoma, Small Cell with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Carcinoma, Small Cell · United States.

Enrollment
5th of 38
139 · median 36
Started
2015
with 1 other
Phase 2
18 of 40
1 open now
Registered
20th of 40
by date
Lead sponsor
2 of 40
EpicentRx, Inc.

Among the 40 studies in Carcinoma, Small Cell with a site in United States, this one is the 5th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2015, is one of 18 in phase 2, and was the 20th registered.

Carcinoma, Small Cell

69 studies on the registry are indexed under Carcinoma, Small Cell; 13 are open to participants now.

Browse Carcinoma, Small Cell studies →

Open to participants now

3 of the 40 studies in Carcinoma, Small Cell with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Carcinoma, Small Cell studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Small Cell with a site in United States, or all of them as a file.
02

Study summary

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Read the detailed description

This is an open label, four 'cohort' study for administration of RRx-001 with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy according to the treatment schedule listed below. Small cell carcinoma and ovarian cohort participants will be randomized to 1 of 2 treatment arms, respectively. Neuroendocrine and NSCLC patients will be enrolled to single arms.

Participants with SCC will receive one of the following; RRx-001 followed by platinum doublet chemotherapy or platinum based chemotherapy alone. HGNEC, RRx-001 followed by platinum doublet chemotherapy. NSCLC, RRx-001 followed by platinum doublet chemotherapy. Participants with Platinum Refractory/Resistant Ovarian and MMMT will receive one of the following, RRx-001 followed by platinum doublet chemotherapy or chemotherapy alone.

Approximately 213 participants will be enrolled.

03

Conditions studied

  • Small Cell Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Neuroendocrine Tumors
  • Ovarian Epithelial Cancer

Keywords

  • Epigenetics
  • resensitization
  • Platinum doublets
  • lung cancer
  • Ovarian epithelial cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed advanced or :

    • Resistant/ Small Cell Carcinoma (SCC) patients in or beyond that have previously received platinum or patients in 2nd line with platinum-refractory or platinum-resistant disease
    • EGFR mutated non-small cell lung cancer (NSCLC) that has previously received a first line platinum doublet and all applicable EGFR TKIs
    • Epithelial Ovarian Cancer (EOC), fallopian tube or primary peritoneal cancer and Malignant Mixed Mullerian Tumor (MMMT) of the ovary or uterus. Excludes other non-epithelial ovarian tumors and ovarian tumors with low malignant potential. Patients must have previously received a platinum based regimen for advanced/metastatic disease or have platinum resistant or refractory disease defined as relapse within 6 months. EOC - specific criteria: Patients who progress or have stable disease during first-line treatment or who relapse within 1 month are considered to be 'platinum-refractory'. Patients who respond to primary treatment and relapse within 6 months are considered 'platinum-resistant', and patients who relapse more than 6 months after completion of initial therapy are characterized as 'platinum-sensitive'. Patients who relapse 6-12 months following the end of their initial regimen are classified as 'partially sensitive'. Platinum sensitive patients may be enrolled but must have failed or declined all other lines of FDA approved therapy
    • High-Grade Neuroendocrine Carcinoma (HGNEC), any organ of origin, including a pathology of neuroendocrine features, in patients previously been treated with chemotherapy Although neuroendocrine tumors may be classified differently based on organ of origin, in the context of this protocol they are defined as high grade on the basis of either

      1. Aggressive clinical behavior requiring previous treatment with chemotherapy even if histologic features such as the Ki67 index or mitotic rate corresponds with low or intermediate grade.
      2. Histologic features: (a) Neuroendocrine tumors of lung origin are considered high grade if in any part of the tumors, there are >10 mitoses/2mm2 or 10 high power field (HPF). Large zones of necrosis are usually present. This includes small cell lung carcinoma and large cell neuroendocrine lung carcinoma. [SCLC will not enroll in the HGNEC cohort.] (b)Neuroendocrine tumors of gastroenteropancreatic origin are considered high grade if in any part of the tumors there are either >20 mitoses/2mm2 or 10 high power field (HPF) OR Ki67.
  • Radiographically by v1.1
  • A of 3-weeks from last treatment.
  • Patients must have previously received a platinum based regimen for advanced/metastatic disease and progressed or have platinum resistant or refractory disease defined as relapse within 6 months.
  • Age ≥18 years.
  • of ≥12 weeks.
  • performance status 0-2.
  • Participants must have adequate organ and marrow function as defined below both prior to administration of RRx-001 and prior to administration of platinum doublet based regimen:

    • ≥1,500/mcL
    • ≥100,000/mcL (non-transfused platelet count)
    • ≥9 g/dL (transfused Hgb allowed)
    • Creatinine ≤1.5 x the
    • Total ≤2.0 x the upper limit of normal or \<3.0 xULN if patient has a history of Gilbert's syndrome
    • (SGOT)/ALT (SGPT) ≤5 X institutional upper limit of normal if with liver metastases; ≤2.5 X ULN if no liver metastases
  • Patient must consent to the access, review and analysis of previous medical and cancer history, including tumor (if available) and imaging data by the sponsor or a third party nominated by the sponsor.
  • Ability to understand and sign a written document.
  • Women of and men with partners of child-bearing potential must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.

    • Note: A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been for at least 12 consecutive months

Exclusion criteria

Exclusion Criteria

  • Receiving concurrent therapy
  • Symptomatic central nervous system (e.g., patients requiring increasing doses of )
  • History of needing to permanently discontinue prior platinum doublet-based regimen for toxicity (e.g., cisplatin causing renal impairment, ototoxicity, or severe neuropathy).
  • Known severe to the platinum agent (i.e., carboplatin or cisplatin) or prior partner of platinum agent (i.e., etoposide for SCC and HGNEC; nab-paclitaxel, paclitaxel, or pemetrexed for NSCLC; paclitaxel, pegylated liposomal doxorubicin, docetaxel or gemcitabine for ovarian) planned for the platinum therapy period. If the patient has had prior hypersensitivity reaction to the drug partner of platinum, a patient may enroll as long as it is acceptable to treat with platinum and one of the alternative chemotherapy partner agents.
  • Any significant medical diseases or conditions, as assessed by the investigators and sponsor that would substantially increase the medical risks of participating in this study (i.e., uncontrolled diabetes, II-IV congestive heart failure, myocardial infarction within 6 months of study, severe chronic pulmonary disease or active uncontrolled infection, uncontrolled or pulmonary edema).
  • Pregnant or nursing
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Small Cell Lung Cancer (Arm 1)

    RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).

    Drug: RRx-001 · Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin

  • Active comparator
    Small Cell Lung Cancer (Arm 2)

    Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity

    Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin · Drug: Irinotecan · Drug: Vinorelbine

  • Experimental
    Non Small Cell Lung Cancer

    RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).

    Drug: RRx-001 · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Pemetrexed

  • Experimental
    Neuroendocrine tumors

    RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).

    Drug: RRx-001 · Drug: Cisplatin · Drug: Etoposide · Drug: Carboplatin

  • Experimental
    Ovarian epithelial cancer (Arm 1)

    RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).

    Drug: RRx-001 · Drug: Carboplatin

  • Active comparator
    Ovarian epithelial cancer (Arm 2)

    Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity

    Drug: Etoposide · Drug: Carboplatin · Drug: Vinorelbine · Drug: Doxil · Drug: Gemcitabine · Drug: Taxane

06

What researchers measure

Primary outcomes

  1. Overall Survival

    From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.

    Time frame: From start of treatment through death for up to 64 months from Start of Treatment.

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate (ORR) will be defined as the proportion of patients with a CR or a PR per RECIST v1.1 based upon the best response as assessed; confirmation of response was not required, assessed up to 49 months.

    Time frame: Assessed up to 49 months

  2. Disease Control Rate (DCR)

    The percentage of patients who have achieved complete response, partial response and stable disease (as per RECIST v1.1), assessed up to 49 months.

    Time frame: Assessed up to 49 months

  3. Progression Free Survival (PFS)

    Progression-free survival (PFS) will be defined as the elapsed time from the from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 49 months.

    Time frame: Assessed up to 49 months

07

Results

Posted Mar 17, 2025

Participant flow

Participants were recruited based on physician referral at 13 academic medical centers between June 2015 and October 2020. The first participant first visit was June 12, 2015 and the last patient last visit was October 8, 2020.

Screening
Participant flow — Screening
MilestoneRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Screening (Pre-Randomization) (A10)
Started1180021
Completed940013
Not completed24008
Withdrew: Screen failure24008
Randomized and Received Treatment
Participant flow — Randomized and Received Treatment
MilestoneRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Screening (Pre-Randomization) (A10)
Started941120
Completed75720
Not completed19400
Withdrew: Protocol violation0100
Withdrew: Baseline drop out3000
Withdrew: Withdrawal by subject6200
Withdrew: Death10100

Outcome measures

PrimaryOverall Survival

From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.

Time frame:
From start of treatment through death for up to 64 months from Start of Treatment.
Reported as:
Mean · Months
Overall Survival
MonthsRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)
Overall Survival6.85 (5.80 to 8.62)7.6 (5.00 to NA)7.5 (3.00 to NA)
SecondaryOverall Response Rate (ORR)

Overall Response Rate (ORR) will be defined as the proportion of patients with a CR or a PR per RECIST v1.1 based upon the best response as assessed; confirmation of response was not required, assessed up to 49 months.

Time frame:
Assessed up to 49 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)
Overall Response Rate (ORR)3231
SecondaryDisease Control Rate (DCR)

The percentage of patients who have achieved complete response, partial response and stable disease (as per RECIST v1.1), assessed up to 49 months.

Time frame:
Assessed up to 49 months
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)
Disease Control Rate (DCR)4282
SecondaryProgression Free Survival (PFS)

Progression-free survival (PFS) will be defined as the elapsed time from the from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 49 months.

Time frame:
Assessed up to 49 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)
Progression Free Survival (PFS)5.87 (4.46 to 7.54)6.50 (NA to NA)12 (NA to NA)

Adverse events

Collected over Adverse Events were collected beginning at baseline through end of treatment (28 days after last dose of study drug), up to 64 months. All-Cause Mortality was assessed from baseline through 28 days after last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RRx-001 + Platinum Doublet (A01-09)89/89 (100%)55/89 (61.8%)89/89 (100%)
RRx-001 + Platinum + RRx-001 (A10)10/10 (100%)6/10 (60%)10/10 (100%)
Investigator's Choice (A10)2/2 (100%)2/2 (100%)2/2 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)
Inappropriate antidiuretic hormone secretionMetabolism and nutrition disorders0/892/102/2
AnaemiaBlood and lymphatic system disorders4/891/101/2
EmbolismVascular disorders1/890/101/2
ThrombocytopeniaBlood and lymphatic system disorders1/891/100/2
Atrial fibrillationCardiac disorders2/891/100/2
Intestinal perforationGastrointestinal disorders0/891/100/2
Small Intestinal ObstructionGastrointestinal disorders3/891/100/2
Mental status changesPsychiatric disorders1/891/100/2
Acute kidney injuryRenal and urinary disorders1/891/100/2
Urinary tract obstructionRenal and urinary disorders1/891/100/2
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)
AnaemiaBlood and lymphatic system disorders12/898/102/2
ThrombocytopeniaBlood and lymphatic system disorders6/894/101/2
ConstipationGastrointestinal disorders20/892/101/2
NauseaGastrointestinal disorders12/894/101/2
FatigueGeneral disorders18/894/101/2
Infusion related reactionInvestigations18/894/101/2
NeutropeniaBlood and lymphatic system disorders9/893/100/2
Abdominal painGastrointestinal disorders9/893/100/2
VomitingGastrointestinal disorders5/892/100/2
HeadacheNervous system disorders8/892/100/2

Baseline characteristics

Safety Population comprises all subjects who are randomized and received at least 1 dose of study drug and will be used for all analyses of safety. Analysis is based on actual treatment group

Age, Continuous
Age, Continuous(years)RRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Total
Mean61.4 ± 11.361.3 ± 6.175.0 ± 2.861.6 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)RRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Total
Female488056
Male463251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Total
Hispanic or Latino3104
Not Hispanic or Latino88102100
Unknown or Not Reported3003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Total
American Indian or Alaska Native0000
Asian7108
Native Hawaiian or Other Pacific Islander3003
Black or African American100010
White749285
More than one race0000
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)RRx-001 + Platinum Doublet (A01-09)RRx-001 + Platinum + RRx-001 (A10)Investigator's Choice (A10)Total
United States94112107
08

Study locations

10 sites
  • Stanford University
    Palo Alto, California 94304, United States
  • VA Connecticut Cancer Center
    West Haven, Connecticut 06516, United States
  • Memorial Hospital of South Bend
    South Bend, Indiana 46601, United States
  • Baptist Health
    Lexington, Kentucky 40503, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Henry Ford Allegiance Health
    Jackson, Michigan 49201, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • University of Cincinnati Cancer Institute
    Cincinnati, Ohio 45267, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
09

References and documents

Publications

  • Tomita Y, Oronsky B, Abrouk N, Cabrales P, Reid TR, Lee MJ, Yuno A, Baker J, Lee S, Trepel JB. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit. Transl Lung Cancer Res. 2021 Jan;10(1):274-278. doi: 10.21037/tlcr-20-359. PubMed 33569311 ↗
  • Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br J Cancer. 2019 Jul;121(3):211-217. doi: 10.1038/s41416-019-0504-8. Epub 2019 Jun 24. PubMed 31231122 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Dec 2021, 78 months.

Results were first posted in Mar 2025, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2015
First posted
Jul 3, 2015
StartActual
Jun 2015
Primary completionActual
Dec 6, 2021
CompletionActual
Dec 6, 2021
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02489903
Lead sponsor
EpicentRx, Inc.
Responsible party
Sponsor
First posted
Jul 3, 2015
Start date
Jun 2015
Primary completion
Dec 6, 2021
Completion
Dec 6, 2021
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Study contacts

Bryan Oronsky, MD, PhD
study director · EpicentRx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: RRx-001 · Cisplatin · Etoposide

Start the discussion